title: Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.
abstract: With the advent of the direct acting antivirals (DAA), or all oral HCV treatment regimens, there exists a great opportunity to provide HCV treatment to people who inject drugs (PWID) enrolled in an opioid treatment program (OTP). This retrospective study conducted in the context of routine clinical care explores the outcomes of HCV treatment with DAAs in PWID enrolled in an OTP. Our study showed treatment outcomes among our first 75 patients treated with DAAs were nearly equivalent to patients in the general population. Ninety-eight percent of patients completing treatment obtained a sustained virologic response, with 10 patients lost to follow-up. Ninety-nine percent of patients adhered to HCV treatment. Ongoing drug use occurred in 23% of patients, however this did not alter HCV treatment outcomes. Treating HCV infection with DAAs in PWID onsite in an OTP is feasible.
authors.affiliation: Yale University School of Medicine, Department of Internal Medicine, United States; APT Foundation, New Haven, CT, United States. Electronic address: Jenna.butner@yale.edu.
authors.forename: Jenna L
authors.initials: JL
authors.lastname: Butner
authors.affiliation: Yale University School of Medicine, Department of Internal Medicine, United States.
authors.forename: Neil
authors.initials: N
authors.lastname: Gupta
authors.affiliation: APT Foundation, New Haven, CT, United States.
authors.forename: Chris
authors.initials: C
authors.lastname: Fabian
authors.affiliation: APT Foundation, New Haven, CT, United States.
authors.forename: Susan
authors.initials: S
authors.lastname: Henry
authors.affiliation: Yale University School of Medicine, Department of Internal Medicine, United States; APT Foundation, New Haven, CT, United States.
authors.forename: Julia M
authors.initials: JM
authors.lastname: Shi
authors.affiliation: Yale University School of Medicine, Department of Internal Medicine, United States; APT Foundation, New Haven, CT, United States.
authors.forename: Jeanette M
authors.initials: JM
authors.lastname: Tetrault
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003237:Connecticut; D005260:Female; D040261:Harm Reduction; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D058850:Opiate Substitution Treatment / Q000379:methods; D009293:Opioid-Related Disorders / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D016320:Substance Abuse Treatment Centers; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
keywords: Direct acting antivirals (DAA); Hepatitis C (HCV); Opioid treatment program (OTP); People who inject drugs (PWID); Substance use disorder (SUD)